Newsroom
May 19, 2026
Scientists at The University of Texas at San Antonio (UT San Antonio) are investigating a major immune system pathway that leads to the development of chronic pain and a drug that has the potential to stop the process in its tracks. Their study, published April 22 in Cell Reports, is the first of its kind to show a path toward the prevention of chronic pain.
April 23, 2026
Written by: Claire Kowalick More than 70% of cancers — including breast, bladder, cervical and lung cancer — show evidence of mutations linked to a group of enzymes called apolipoprotein B mRNA-editing enzyme catalytic polypeptides, or APOBEC. “APOBEC mutagenesis is the second-largest source of mutation in cancer and, importantly, the largest one we can do […]
April 17, 2026
Texas Public Radio: A therapy that could revolutionize cancer treatment is getting a clinical trial in San Antonio
April 13, 2026
For more than 20 years, Lixin Song, PhD, RN, FAAN, vice dean for research and scholarship and professor of nursing at The University of Texas at San Antonio (UT San Antonio) School of Nursing, has studied how cancer patients and their families navigate the challenging experience of making decisions about treatment while facing uncertainty, […]
March 24, 2026
UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer study, marking a pivotal moment for science and patient-centered cancer care in San Antonio and South Texas.
March 2, 2026
A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.
